BIR
The British Institute of Radiology

22 JANUARY 2021



APPROVED BY THE BIR

STATE-OF-THE-ART NUCLEAR MEDICINE AND PIPELINE INDUSTRY DEVELOPMENTS

Virtual event

CPD: 2 CREDITS

Bayer have part funded this event

PHILIPS

SIEMENS Healthineers

Advanced Accelerator Applications
A Novartis Company

STATE-OF-THE-ART NUCLEAR MEDICINE AND PIPELINE INDUSTRY DEVELOPMENTS

Virtual event

CPD: 2 credits

13:00	**Welcome and introduction** Dr Shaunak Navalkissoor, Consultant in Nuclear Medicine, Royal Free London NHS Foundation Trust
13:10	**The journey from research to clinical usage – an industry perspective** Dr Ted Broadbent, Vice-President Supply Chain and EU Commercial, Blue Earth Diagnostics
13:50	**Rhenium-SCT®: New method for the treatment of basal and squamous cell carcinoma** Dr Gerhard Dahlhoff, Chief Medical Director, OncoBeta
14:30	**Clinical dosimetry made practical** Mr David Mirando, Senior Clinical Engineer, MIM Software Inc.
15:10	**Close of event**

This course provides 2 CPD credits in accordance with the CPD Scheme of the Royal College of Radiologists

22
JANUARY
2021

Programme organiser

Dr Shaunak Navalkissoor, Consultant in Nuclear Medicine, Royal Free London NHS Foundation Trust

With thanks to our sponsors

BLUE EARTH DIAGNOSTICS
A Bracco Company

mim SOFTWARE

ONCOBETA®
epidermal radioisotope therapy

Let's talk about your dosimetry workflow.

Not all dosimetry solutions are the same.

Nuclear Medicine requires a comprehensive MRT solution that improves dosimetry practices without adding significant time to the workflow.

MIM SurePlan™ MRT

Advancing Molecular Radiotherapy

Calculating patient-specific dose doesn't have to add significant time to your workflow. MIM SurePlan MRT provides a single solution for effective dosimetry, organ and tumor segmentation, deformable registration, and communication tools that help reduce clinical effort.

Timesaving Tools

Automated segmentation significantly reduces the time required to generate organ volumes, such as the kidneys and liver. Industry-leading PET and SPECT segmentation tools are available for tumors and other volumes of interest (VOIs).

Multi-Tracer Theranostics Support

MIM SurePlan MRT offers imaging tools for multiple Molecular Radiotherapy tracers, such as Lu-177 dotatate, I-131 mIBG, [I-131] NAI for thyroid, and more, providing confirmation of dose delivery in the patient.

Quantitative SPECT and Planar Corrections

No new cameras required. SPECTRA Quant™ provides dosimetry with vendor-neutral quantitative SPECT reconstruction. Generate quantitative images from imaging to measure dose as opposed to measuring the amount of activity from user to user.

Visit **https://go.mimsoftware.com/eu/personalized-dosimetry** to schedule a demo or learn more.

MIM Software Inc. • 25800 Science Park Drive - Suite 180, Cleveland, Ohio 44122 • 866-421-2536

ONCOBETA®

Rhenium-SCT®

Epidermal Radioisotope Therapy

A new nuclear medical intervention for treatment of

Basal cell carcinoma

and

Squamous cell carcinoma

1x single session

aesthetic

non-invasive

painless

Bringing back
Quality of Life.

Learn more in
www.oncobeta.com

Biographies

Dr Shaunak Navalkissoor
Consultant in Nuclear Medicine, Royal Free London NHS Foundation Trust

Dr Shaunak Navalkissoor is a Consultant Nuclear Medicine Physician, working at the Royal Free London NHS Foundation Trust. He was appointed in 2010.His special interests include radionuclide therapy and oncological imaging. He has a particular interest in imaging and therapy of neuroendocrine tumours in which he has several peer reviewed publications and has been the principal investigator for several clinical trials. He is actively involved in the MSc Nuclear Medicine Course (King's College London) and is the current chair of the British institute of radiology nuclear medicine subgroup.

Dr Ted Broadbent
Vice-President of Supply Chain and EU Commercials, Blue Earth Diagnostics

Dr Ted Broadbent is VP Supply Chain and EU Commercial at Blue Earth Diagnostics. Before joining Blue Earth Diagnostics, Ted managed the PET Network for GE Healthcare Life Sciences in Europe, Middle East and Africa. He has previously held positions in sales, marketing, R & D and business development at GE Healthcare, Amersham plc., Molecular Dynamics, BTTG and Bio/Gene. Ted has an undergraduate degree in Life Sciences from the University of Liverpool and a doctorate in Molecular Pathology from the University of Leeds.

Dr Gerhard Dahlhoff
Chief Medical Director, OncoBeta

Dr Gerhard Dahlhof studied medicine in Ulm and Munich from 1986 to 1992. He completed the assistant period in Augsburg, Munich and Lauingen. He passed the specialist examination in surgery in 2001. He graduated with additional Master of Business Adminsistrator 2000 in Laar (Germany). He worked as a Senior Physician in Lauingen (Germany) from 1998 to 2000 and at the University of St Gallen (Switzerland) 2000 until 2002. He joined the AOK Bayern (third biggest health insurance company of Germany) in 2002-2016 as Chief Medical Director. He took over in 2017 as Chief Medical Director at OncoBeta GmbH and OncoBeta international.

Mr David Mirando
Clinical Engineer, MIM Software Inc.

Mr David Mirando has worked on research and development of clinical tools for molecular radiotherapy dosimetry for over three years. During this time, he has presented at a number of large nuclear medicine conferences on new findings on accuracy and automation improvements that can be achieved with software support tools. Most recently he presented at the virtual EANM 2020 meeting with a presentation entitled: "In pursuit of fully automated dosimetry: evaluation of an automatic VOI propagation algorithm using contour intensity-based SPECT alignments." He studied biomedical and electrical engineering at Case Western Reserve University, and is dedicated to improving patient care in the field of oncology.

STATE-OF-THE-ART NUCLEAR MEDICINE AND PIPELINE INDUSTRY DEVELOPMENTS

Virtual

BIR
The British Institute of Radiology

@BIR_News
/britishinstituteofradiology
The British Institute of Radiology

48–50 St John Street, London, EC1M 4DG
www.bir.org.uk

Registered charity number: 215869

APPROVED BY THE BIR